Position Statements

  Date Type Size Document Notes
  February 2009 PDF   Society for Endocrinology position statement on the use of dopamine agonists in endocrine disorders.

This statement has been issued in response to the information contained in the MHRA Drug Safety Update (Volume 2, Issue 3 October 2008).
  January 2009 LINK   Statement on the diagnosis and management of hypothyroidism. (The statement is available on the RCP website)

The Society for Endocrinology in association with the Royal College of Physicians and a number of other Societies has prepared this statement in response to concerns about diagnostic tests and ‘natural’ treatments for thyroid disease. 
Acrobat Icon September 2006 PDF 63kb Somatostatin Analogues and GH Receptor Antagonist in Patients with Acromegaly  
Acrobat Icon March 2006 PDF 25kb Society Endorsement document A policy for dealing with requests for endorsements of other organisations' documents
SfE HTML Document June 2005 HTML   Response to NICE consultation document on Social Value Judgements  
SfE HTML Document June 2005 HTML   Use of animals in medical research  
SfE HTML Document January 2005 HTML   Hypogonadism of ageing - does low testosterone in ageing men require treatment?  
SfE HTML Document September 2004 HTML   Society statement on testosterone The Society is concerned about inappropriate testosterone therapy. This statement seeks to clarify the Society's view.
Acrobat Icon   PDF 171kb The use of growth hormone replacement in adult patients with severe growth hormone deficiency